Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Zhang, Yuchen; Li, Panpan; Cai, Jun; Jing, Hongmei; Zou, Liqun; Huang, Huiqiang; Wu, Yuanbin; Li, Wenyu; Zhong, Liye; Jin, Xueli; Ye, Xu; Feng, Ru; Zhang, Huilai; Zhang, Liling; Lin, Lianbo; Sun, Xiuhua; Tian, Yuzhou; Xia, Zhong‐Jun; Li, Zhiming; Huang, He; Xia, Yi; Cai, Qingqing

doi:10.1002/cam4.4765

Cited by 4 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment strategies reported in the first study resulted in a median PFS of 30.8 months, an ORR of 84.9%, and a CR of 43.4%, with a median follow-up of 20.5 months (for the overall study population). 24 Moreover, the efficacy of ibrutinib plus venetoclax in the second study was reported in terms of ORR and CR, which were 100% and 50%, respectively. 39…”

Section: Resultsmentioning

confidence: 94%

“…Two studies analyzed the efficacy of ibrutinib in combination with other agents. The first one reported the outcomes of ibrutinib combined with several other agents (rituximab, lenalidomide, bortezomib, and/or bendamustine) in 53 patients (75.5% males, median age of 56 years), 24 of which 28.3%, 84.9%, 51.0%, and 54.7% had an ECOG score ≥2, a III–IV stage R/R-MCL, an intermediate-high sMIPI, and a Ki-67 index ≥30%, respectively. In addition, the percentages of patients with a previous auto-SCT, refractoriness to the most recent line of therapy, and blastoid histology were 9.4%, 47.2%, and 19.2%.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 300 publications were identified using the described search strategies. After removing all duplicates and excluding studies that did not meet the inclusion criteria, a total of 25 journal articles -18 original articles, [8][9][10][11]14,[21][22][23][24][25][26][27][28][29][30][31][32][33] 3 letters to the editor, [34][35][36] 3 short reports, 13,37,38 and 1 case report 39 and 5 conference publications [40][41][42][43][44] were included in the systematic review. All the 30 studies allowed the data collection of 37 treatment regimens for R/R MCL patients.…”

Section: Resultsmentioning

confidence: 99%

“…Regarding survival outcomes, the highest median PFS values were found with ibrutinib 21 , 24 and bendamustine (median PFS ranging from 10.1 to 25.9 months) 9 , 28 regimens. The ibrutinib-based treatment regimens resulted in a wide range of median PFS values, from 7.9 to 30.8 months.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review

Sancho,

Sorigué,

Rubio-Azpeitia

2024

JBM

View full text Add to dashboard Cite

Introduction Mantle cell lymphoma (MCL) is an incurable disease with an aggressive clinical course, and most patients eventually relapse after chemotherapy. Targeted therapies developed for relapsed/refractory MCL have been approved based on clinical trial data. However, real-world setting data are scarce and scattered. Areas Covered This systematic review aimed to collect, synthesize, and describe the characteristics and treatment outcomes of patients with relapsed/refractory MCL after receiving a second or subsequent line of therapy in the real-world setting. Expert Opinion R/R MCL is clinically and biologically heterogeneous and still represents a therapeutic challenge, with high-risk and early relapsed patients remaining an unmet medical need. This systematic review is limited by the quality of the available data and the difficulty of comparing outcomes in R/R MCL due to the heterogeneity of the disease, but the results suggest that covalent BTKis should be positioned as second-line therapy, followed by CAR T-cells in BTK-i-relapsed patients. Chemo-free and combination therapies with established chemoimmunotherapy backbones in the relapsed and front-line settings have been recently developed, and front-line options are being improved to move targeted and cellular therapies to earlier lines, including front-line therapy, in elderly and younger fit patients. In the upcoming years, many new targeted agents will play an important role and will be incorporated to the routine practice as their sequence, and outcomes in unselected patients are determined.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review

Sancho,

Sorigué,

Rubio-Azpeitia

2024

JBM

View full text Add to dashboard Cite

show abstract

“…The lack of OS benefit across the years may be due to the fact that OS is influenced by subsequent regimens. Interestingly, the abovementioned OS benefit during the last 5 years for elderly patients could be due to the introduction of ibrutinib as a second-line regimen in Italy, unlike its limited use in Finland, where it is reimbursed as a fourth-line regimen [ 29 , 35 , 43 , 44 , 45 , 46 ]. The main limitation of our study is represented by the retrospective nature of the study and the reduced sample size, and this may explain why some classic prognostic factors, such as MIPI score and stage, did not affect PFS and OS in our cohort.…”

Section: Discussionmentioning

confidence: 99%

Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study

Cencini,

Calomino,

Franceschini

et al. 2024

Hematology Reports

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) prognosis has significantly improved in recent years; however, the possible survival benefit of new treatment options should be evaluated outside of clinical trials. We investigated 73 consecutive MCL patients managed from 2006 to 2020. For younger patients <65 years old, the median PFS was 72 months and we reported a 2-year, 5-year, and 10-year PFS of 73%, 62%, and 41%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 88%, 82%, and 66%. For patients aged 75 years or older, the median PFS was 36 months and we reported a 2-year, 5-year, and 10-year PFS of 52%, 37%, and 37%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 72%, 55%, and 55%. The median PFS was significantly reduced for patients treated between 2006 and 2010 compared to patients treated between 2011 and 2015 (p = 0.04). Interestingly, there was a trend towards improved OS for patients treated between 2016 and 2020 compared to between 2006 and 2010 and between 2011 and 2015 (5-year OS was 91%, 44%, and 33%). These findings could be due to the introduction of BR as a first-line regimen for elderly patients and to the introduction of ibrutinib as a second-line regimen.

show abstract